Phathom Pharmaceuticals (PHAT) Accumulated Expenses (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Accumulated Expenses data on file, last reported at $83.3 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 4521.02% year-over-year to $83.3 million in Q1 2026; TTM through Mar 2026 was $83.3 million, a 4521.02% increase from a year earlier, with the FY2025 full-year figure at $1.8 million, down 96.56% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $83.3 million, up from $1.8 million in the prior quarter.
• Over the last five years, Accumulated Expenses for PHAT reached as high as $83.3 million in Q1 2026 and fell as low as $686000.0 in Q3 2022.
• Historically, Accumulated Expenses has averaged $18.4 million across 5 years, with a median of $7.6 million in 2022.
• Across the five-year window, Accumulated Expenses jumped 4545.03% in 2024 and sank 96.56% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $8.4 million in 2022, then slumped by 86.43% to $1.1 million in 2023, then soared by 4545.03% to $53.2 million in 2024, then sank by 96.56% to $1.8 million in 2025, then surged by 4445.39% to $83.3 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $83.3 million in Q1 2026, $1.8 million in Q4 2025, and $65.3 million in Q3 2025.